Newer agents for blood glucose control in type 2 diabetes: summary of NICE guidance.
Adler
Amanda I
AI
Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ. aia31@medschl.cam.ac.uk
Shaw
Elizabeth J
EJ
Stokes
Tim
T
Ruiz
Francis
F
D001786:Blood Glucose; D003657:Decision Making; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use; D000077270:Exenatide; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000627:therapeutic use; D010455:Peptides / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D045162:Thiazolidinediones / Q000627:therapeutic use; D014688:Venoms / Q000627:therapeutic use
D001786:Blood Glucose; D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents; D007328:Insulin; D010455:Peptides; D045162:Thiazolidinediones; D014688:Venoms; D000077270:Exenatide